insights_auto
Zašto je NTLA pao 2,24%?
Istražite detaljnijechevron_right
NTLA:NASDAQ
Intellia Therapeutics Inc
12,46 USD
arrow_downward
−2,24%(−0,28) 1D
6. lis, 14:54:21 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za NTLA...
Otvori
12,50 USD
Najviša
13,22 USD
Najniža
12,04 USD
Trž. kap.
1,68 mlr.
Prosj. kol.
4,08 mil.
Količina
5,96 mil.
52-tjed. najviša
28,24 USD
52-tjed. najniža
7,95 USD
EPS
−3,36 USD
Beta
1,80
Dionice u optjecaju
140,13 mil.
Broj djelatnika
377
Otvori
12,50 USD
Najviša
13,22 USD
Najniža
12,04 USD
Trž. kap.
1,68 mlr.
Prosj. kol.
4,08 mil.
Količina
5,96 mil.
52-tjed. najviša
28,24 USD
52-tjed. najniža
7,95 USD
EPS
−3,36 USD
Beta
1,80
Dionice u optjecaju
140,13 mil.
Broj djelatnika
377
Vijesti
Iz web-izvora i od partnera za vijesti
Benzinga
·
prije 3 sata
Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile Up
GuruFocus
·
prije 5 sati
NTLA Initiates Coverage On Barclays -- Rating Set to Underweight
Kalkine Media
·
prije 21 sat
Intellia Therapeutics Officer Files Form 144 to Sell 57,750 Shares Following Option Exercise
Seeking Alpha
·
prije 1 dan
Cathie Wood's Ark Invest weekly recap: loads up on Nvidia, Intellia; pares AMD (ARKK:BATS)
Profil
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
The CRISPR gene editing system was originally invented by Jennifer Doudna, one of Intellia's scientific founders, and Virginijus Šikšnys. The company has entered into a number of different research and development collaborations with leading and emerging biotechnology companies including Novartis, Regeneron, Avencell, SparingVision, Kyverna, and ONK Therapeutics.
Intellia has two in vivo programs in ongoing clinical trials. NTLA-2001 is an investigational CRISPR therapy candidate for the treatment for ATTR amyloidosis currently in Phase 1 studies. Wikipedia
Intellia Therapeutics Inc – informacije
Glavni izvršni direktorJohn Leonard
Zaposlenici377
Osnovano2014
SjedišteCambridge, Massachusetts, Sjedinjene Američke Države
Sektor-
Web-lokacijaintelliatx.com